Omeros (OMER) Non Operating Income (2010 - 2022)
Omeros recorded quarterly Non Operating Income of $670000.0 in Q2 2022, up 35.9% quarter-over-quarter from $493000.0 in Q1 2022, and up 101.2% year-over-year from $333000.0 in Q2 2021.
Omeros' Non Operating Income history runs 13 years deep, the most recent figure standing at $670000.0 for Q2 2022.
- In Q2 2022, Non Operating Income rose 101.2% year-over-year to $670000.0; the TTM figure through Jun 2022 stood at $2.2 million (up 336.99% YoY), while the FY2021 annual figure was $1.7 million, up 166.06% from the prior year.
- Non Operating Income came in at $670000.0 for Q2 2022 at Omeros, up from $493000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $670000.0 in Q2 2022 to a low of -$633000.0 in Q3 2020.
- A 5-year average of $382833.3 and a median of $439000.0 in 2018 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income tumbled 279.32% in 2020 and surged 172.83% in 2021, its largest moves.
- Omeros' Non Operating Income stood at $153000.0 in 2018, then jumped by 90.85% to $292000.0 in 2019, then grew by 28.08% to $374000.0 in 2020, then jumped by 40.64% to $526000.0 in 2021, then gained by 27.38% to $670000.0 in 2022.
- According to Business Quant data, Non Operating Income over the past three periods registered $670000.0, $493000.0, and $526000.0 for Q2 2022, Q1 2022, and Q4 2021 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 670,000.00 |
| Mar 31, 2022 | 493,000.00 |
| Dec 31, 2021 | 526,000.00 |
| Sep 30, 2021 | 461,000.00 |
| Jun 30, 2021 | 333,000.00 |
| Mar 31, 2021 | 418,000.00 |
| Dec 31, 2020 | 374,000.00 |
| Sep 30, 2020 | -633,000.00 |
| Jun 30, 2020 | 364,000.00 |
| Mar 31, 2020 | 549,000.00 |
| Dec 31, 2019 | 292,000.00 |
| Sep 30, 2019 | 353,000.00 |
| Jun 30, 2019 | 415,000.00 |
| Mar 31, 2019 | 494,000.00 |
| Dec 31, 2018 | 153,000.00 |
| Sep 30, 2018 | 572,000.00 |
| Jun 30, 2018 | 597,000.00 |
| Mar 31, 2018 | 460,000.00 |
| Dec 31, 2017 | 434,000.00 |
| Sep 30, 2017 | 408,000.00 |
| Jun 30, 2017 | 303,000.00 |
| Mar 31, 2017 | 299,000.00 |
| Dec 31, 2016 | 272,000.00 |
| Sep 30, 2016 | 211,000.00 |
| Jun 30, 2016 | 174,000.00 |
| Mar 31, 2016 | 288,000.00 |
| Sep 30, 2015 | 251,000.00 |
| Jun 30, 2015 | 224,000.00 |
| Mar 31, 2015 | 218,000.00 |
| Dec 31, 2014 | 165,000.00 |
| Sep 30, 2014 | -251,000.00 |
| Jun 30, 2014 | 165,000.00 |
| Mar 31, 2014 | -286,000.00 |
| Dec 31, 2013 | 153,000.00 |
| Sep 30, 2013 | 154,000.00 |
| Jun 30, 2013 | 155,000.00 |
| Mar 31, 2013 | 112,000.00 |
| Dec 31, 2012 | 160,000.00 |
| Sep 30, 2012 | 159,000.00 |
| Jun 30, 2012 | 152,000.00 |
| Mar 31, 2012 | -341,000.00 |
| Dec 31, 2011 | 171,000.00 |
| Sep 30, 2011 | 171,000.00 |
| Jun 30, 2011 | 171,000.00 |
| Mar 31, 2011 | 184,000.00 |
| Dec 31, 2010 | 1.91 Mn |
| Sep 30, 2010 | 189,000.00 |
| Jun 30, 2010 | 218,000.00 |